drugset / Trial / NCT06143007
A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB3008 as monotherapy in subjects with advanced solid tumors.
Timeline
- Start
- 2023-10-26
- Primary completion
- 2025-05-22
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BB3008 | Unknown | 80 mg | Oral |